Even otherwise healthy children can end up in hospital with this winter respiratory virus.
It takes around 17 years for medical research to translate into clinical practice.
shapecharge/E+ via Getty Images
In health care crises, researchers can avoid waiting for clinical trial results by using data from health care systems to analyze the effectiveness of treatments for COVID-19 and other illnesses.
Alzheimer’s disease is an incapacitating, progressive brain disorder that affects the lives of more than 6.5 million Americans.
PamelaJoeMcFarlane/E+ via Getty Images
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
EPA-EFE/LUONG THAI LINH
In particular, a drug called Evusheld could offer protection for people who are vulnerable – but the UK isn’t offering it.
Broadly neutralizing antibodies are able to recognize multiple strains of HIV at once.
Naeblys/iStock via Getty Images Plus
Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.
The new BA.5 subvariant has caused a sharp rise in cases and hospitalizations throughout much of the United States.
Irfan Khan/Los Angeles Times via Getty Images
Face masks are still an effective way to help stop the spread of the BA.5 subvariant.
An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease.
Kateryna Kon/Science Photo Library via Getty Images
Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
While many immunocompromised and high-risk patients may benefit from AstraZeneca’s Evusheld, drug distribution and access have been uneven.
AP Photo/Ted S. Warren
Evusheld is an antibody drug from AstraZeneca intended to help prevent COVID-19 infection for immunocompromised and other vulnerable patients.
This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).
National Institute of Allergy and Infectious Diseases/Flickr
Although treatments for Ebola have helped many people overcome this deadly disease, the virus can persist in the brain and cause a lethal relapse.
Sotromivab is a monoclonal antibody that binds to the coronavirus to stop it being infectious.
Sotrovimab and baricitinib target COVID at different stages of its development, and will give doctors greater flexibility in treating omicron patients.
Antibodies (light blue) binding to the spike proteins (dark purple) on the outside of the coronavirus.
AstraZeneca’s durable monoclonal antibody treatment has shown promise in phase 3 clinical trials.
Emergency medical technicians aid a COVID-19 patient at his home in Louisville, Kentucky. Like much of the U.S., Louisville is experiencing an uptick in COVID-19 patients requiring emergency transport to medical facilities.
John Cherry/Getty Images
Medications to treat COVID-19 are in no way a substitute for the vaccine. But under the right circumstances, some show great promise for helping patients.
Corona Borealis Studio/Shutterstock
This lab-designed antibody treatment can treat COVID-19 and block infection, though its cost means it may be reserved for the most vulnerable.
The government has ordered 7,700 doses of sotrovimab. But until further evidence shows it’s effective, the guidelines say it should only be given to patients as part of a human clinical trial.
New treatments target different stages of COVID-19, including before patients become sick enough to need a hospital.
Juan Monino via Getty Images
A year after it became clear that COVID-19 was becoming a pandemic, there is still no cure, but doctors have several innovative treatments. Some are keeping patients out of the hospital entirely.
The number one scientific breakthrough for 2020: multiple vaccines to prevent COVID-19.
Philippe Raimbault/Photodisc via Getty Images
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Y-shaped proteins called antibodies are vital for attacking and destroying the virus.
Monoclonal antibodies are synthetic molecules manufactured in the lab. But do we need them if a vaccine is on its way?
Both President Donald Trump and first lady Melania Trump have tested positive for COVID-19.
MANDEL NGAN/AFP via Getty Images
The president and first lady Melania Trump have both tested positive for the coronavirus. Here’s what the physicians and scientists know about the best treatments for the disease it causes.
Experts are confident that there will be a vaccine next year.
PenWin /iStock / Getty Images Plus
As grim as things are with the pandemic raging in the US and the mounting death toll, there are many reasons to be optimistic there will be a vaccine by early next year.
Vaccines and antivirals aren’t the only game in town.